Bank analyst on Novo Nordisk report: Impressive quarter, to say the least

Novo Nordisk has beaten expectations in terms of both its GLP drugs and its obesity treatment, and according to senior equity analyst at Sydbank Søren Løntoft Hansen, the report which Denmark's largest pharmaceutical company sent out Wednesday afternoon is highly impressive.
Photo: Jacob Gronholt-Pedersen/Reuters/Ritzau Scanpix
Photo: Jacob Gronholt-Pedersen/Reuters/Ritzau Scanpix
BY RITZAU FINANS, TRANSLATED BY NIELSINE NIELSEN

The Q2 report that Novo Nordisk introduced on Wednesday afternoon is impressive, to say the least.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading